{"url_path":"/sec/anro/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1999480/0001999480-26-000014-index.html","accession_number":"0001999480-26-000014","cik":"0001999480","ticker":"ANRO","issuer_name":"Alto Neuroscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1999480/0001999480-26-000014-index.html","primary_entity_key":"0001999480","primary_entity_name":"Alto Neuroscience, Inc."},"word_count":85,"has_tables":true,"body_markdown":"Item 9.01    Financial Statements and Exhibits.\n\n(d)Exhibits.\n\nExhibit No.Description\n\n10.1+\n[Amended and Restated 2024 Employee Stock Purchase Plan](exhibit101-altoxar2024empl.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)/\n\n+ Indicates management contract or compensatory plan.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nALTO NEUROSCIENCE, INC.\n\nDated: May 13, 2026By:/s/ Amit Etkin\n\nAmit Etkin, M.D., Ph.D.\n\nPresident and Chief Executive Officer"}